Whalesbook
Solara Pharma Sets Final ₹112.50 Rights Share Payment Deadline for April 2
Solara Active Pharma Sciences has announced its second and final call for payment on its partly-paid rights shares. Shareholders are required to pay ₹112.50 per share, which includes ₹3.00 for the face value and ₹109.50 as premium.
Key Filing Details
The company's Rights Issue Committee approved this final payment demand on March 24, 2026. April 2, 2026, has been set as the record date. This date will determine which shareholders are eligible to receive the official payment notice.
Significance for Investors
This final payment is critical for shareholders aiming to retain their investment in Solara. Failure to meet the ₹112.50 per share deadline will result in the forfeiture of their rights shares. For Solara, this step marks the completion of capital collection from its 2024 rights issue.
Company Background and Financial Context
Solara, a dedicated API manufacturer, operates in India's competitive pharmaceutical market. In May-June 2024, the company launched a rights issue to raise about ₹449.95 Crores, offering shares at ₹375 each. The initial payment was ₹131.25 per share, with the remainder callable within 24 months. Solara has been focusing on improving margins and reducing debt. However, its Q3 FY26 results showed a net loss of ₹17.43 Crores, raising concerns about its going concern status, which depends on securing funds.
Next Steps for Shareholders
Shareholders listed on April 2, 2026, will receive the formal call notice. They must complete the payment of ₹112.50 per share to maintain their stake. Successful collection will help Solara consolidate its capital structure from this rights issue.
Potential Risks
A key risk is shareholder non-payment, which could lead to share forfeiture. Significant defaults could affect the company's cash flow and its ability to meet financial obligations. While Solara is working to improve its financial health, its operational performance remains critical.
Competitive Landscape
Solara competes in the Indian pharmaceutical sector against major companies like Sun Pharma, Divi's Lab, Torrent Pharma, and Zydus Lifesciences, which are all significant players in the API and formulation markets.
Recent Financial Snapshot
For the quarter ending December 31, 2025 (Q3 FY26), Solara reported a consolidated net loss of ₹17.43 Crores, a change from the prior year's profit. Revenue for the same period was ₹349 Crores, showing year-on-year growth.
What to Watch
Investors will monitor shareholder responses to the final call and the total capital collected. Future updates on the company's cash flow, profitability, and debt levels will also be important indicators.